|Dr. Briggs W. Morrison||CEO & Director||872.68k||N/A||1960|
|Mr. Michael A. Metzger||Pres & COO||731.86k||N/A||1971|
|Mr. Richard P. Shea||CFO, Treasurer & Principal Accounting Officer||39k||N/A||1952|
|Dr. Michael L. Meyers M.D., Ph.D.||Chief Medical Officer and Sr. VP||550.81k||N/A||1951|
|Dr. Peter Ordentlich||Co-Founder & CTO||N/A||N/A||1969|
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Syndax Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 7.